Evidence map›Paper›PMID 41535264›Full record

ArticleNature communications2026

Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma.

Yan Zhou, Yingrui Wang, Xiao Shi, Jiatong Wang, Zelin Zang, Likun Zhang, Zhiqiang Gui, Xue Cai, Pingping Hu, Jiaxi Wang and 16 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yan Zhou *College of Life Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0003-3581-4701
Yingrui Wang *Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, Hangzhou, China.ORCID http://orcid.org/0000-0001-5532-3454
Xiao Shi *Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-6803-7438
Jiatong Wang *Affiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, Hangzhou, China.
Zelin Zang *AI Lab, Research Center for Industries of the Future, Westlake University, Hangzhou, China.ORCID http://orcid.org/0000-0003-2831-5437
Likun Zhang *Department of Pathology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiqiang GuiDepartment of Thyroid Surgery, the First Hospital of China Medical University, Shenyang, China.
Xue CaiAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, Hangzhou, China.
Pingping HuAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, Hangzhou, China.
Jiaxi WangDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.ORCID http://orcid.org/0000-0002-8028-8483
Hanqing LiuDepartment of Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Zhihong WangDepartment of Thyroid Surgery, the First Hospital of China Medical University, Shenyang, China.
Haixia GuanDepartment of Endocrinology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0003-3155-2847
Xiaohong WuDepartment of Endocrinology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou, China.
Cenkai ShenDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Yi HeDepartment of Urology, The Second Hospital of Dalian Medical University, Dalian, China.
Mo LiDepartment of Pathology, Liaoning Cancer Hospital & Institute, Shenyang, China.
Hao ZhangDepartment of Thyroid Surgery, the First Hospital of China Medical University, Shenyang, China.ORCID http://orcid.org/0000-0002-9938-8433
Jianbiao WangDepartment of Head and Neck Surgery, Institute of Micro-Invasive Surgery of Zhejiang University, The Affiliated Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yijun WuDepartment of Thyroid Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-6966-744X
Chuang ChenDepartment of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, China.ORCID http://orcid.org/0000-0003-4285-4496
Yi ZhuAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, Hangzhou, China.ORCID http://orcid.org/0000-0003-0429-0802
Yaoting SunAffiliated Hangzhou First People's Hospital, State Key Laboratory of Medical Proteomics, Hangzhou, China. sunyaoting@westlake.edu.cn.ORCID http://orcid.org/0000-0001-7613-648X
Zhiyan LiuDepartment of Pathology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhiyanliu@shsmu.edu.cn.ORCID http://orcid.org/0000-0001-9668-7756
Yu WangDepartment of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. neck130@sina.com.
Tiannan GuoCollege of Life Sciences, Zhejiang University, Hangzhou, China. guotiannan@westlake.edu.cn.ORCID http://orcid.org/0000-0003-3869-7651

Funding

Science and Technology Commission of Shanghai Municipality (Shanghai Municipal Science and Technology Commission) 23ZR1448200
6 · The paper itself

Abstract

Medullary thyroid carcinoma (MTC) is a rare, aggressive neuroendocrine tumor with limited treatment options and frequent recurrence. Comprehensive recurrence risk stratification remains lacking. Here, we profile 482 MTC samples from 452 patients across ten Chinese clinical centers, identifying 10,092 proteins and mutations in 87.0% of patients. Clinically, MTC grading, concurrent papillary thyroid carcinoma, and lymph node metastasis are significant recurrence risk factors, whereas at the genetic level, RET M918T and RET S891A mutations are correlated with high recurrence risk in sporadic and hereditary MTC, respectively. Ubiquitinomics show downregulated E3 ligases CUL4B and TRIM32 are associated with structural recurrence. We define three molecular subtypes with distinct outcomes and present an integrative machine learning model combining clinical, genomic, and proteomic features, validated in an independent test dataset of 105 patients and a published dataset. This multi-center, multi-omics study enhances the understanding of MTC heterogeneity and facilitates personalized patient management.

Indexed as

Carcinoma, NeuroendocrineThyroid NeoplasmsAdultAgedBiomarkers, TumorCullin ProteinsFemaleGenomicsHumansMachine LearningMaleMiddle AgedMultiomicsMutationNeoplasm Recurrence, LocalPrecision MedicineBiomarkers, TumorCullin ProteinsProto-Oncogene Proteins c-retRET protein, humanUbiquitin-Protein Ligases

Identifiers

PMID41535264
PMCPMC12804720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.